Table 1.
Liposome formulations under clinical trial for pediatric cancer *.
| Phase | Drug Loaded | Study Start Date | Study Completion Date | Recruitment Status | Last Update Posted | Ages Eligible for Study | ClinicalTrials.gov Identifier | Type of Cancer |
|---|---|---|---|---|---|---|---|---|
| Phase 1 | Irinotecan | December 2013 | December 2020 | Recruiting | 18 September 2019 | 1 to 20 | NCT02013336 | ST, ES, RhS, NB, OS |
| Phase 1 | Doxorubicin | October 2016 | October 2021 | Recruiting | 25 September 2020 | Up to 30 years | NCT02536183 | ST, RhS, ES, STS, OS, NB, WT, HT, GCT |
| Phase 1 | doxorubicin | July 1999 | - | Completed | 28 April 2015 | Up to 21 years | NCT00019630 | STS, LC, BC, BT, KT |
| Phase 1 | Doxorubicin | December 2016 | 16 March 2019 | Withdrawn | 19 March 2019 | 1 year to 40 years | NCT02557854 | RhS, NB, ES, OS |
| Phase 1 | cytarabine | February 1997 | - | Unknown | 23 March 2010 | 1 year to 21 years | NCT00003073 | CNST, Leukemia, Lymphoma |
| Phase 2 | Daunorubicin | 13 March 2019 | 12 May 2027 | Suspended | 13 February 2020 | 3 months to 17 years | NCT03591510 | FLT3-mutated AML |
| Phase 2 | Daunorubicin | 6 August 2019 | June 2022 | Recruiting | 24 November 2020 | Up to 17 years | NCT03860844 | ALL, AML |
| Phase 2 | Cytarabine | January 2013 | December 2019 | Recruiting | 13 March 2019 | 3 years to 31 years | NCT01859819 | DLCL, BL, HGBL |
| Phase 2 | Cytarabine | January 1996 | June 2004 | Completed | 1 February 2013 | Up to 20 years | NCT00002704 | Leukemia |
| Phase 2 | Vincristine | June 2000 | September 2005 | Completed | 31 October 2018 | Child, adult, older adult | NCT00038207 | STS, WT, OS, Lymphoma, Leukemia |
| Phase 2 | Vincristine | 23 November 2016 | 11 March 2018 | Terminated | 3 April 2019 | Up to 21 years | NCT02518750 | ALL, NHL, Leukemia |
* Data collected on 5 December 2020.